PCRX — PharmaCorp Rx Share Price
Last trade - 00:00- CA$55.72m
- CA$44.00m
- CA$5.79m
- 50
- 19
- 41
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.84 | ||
| Price to Tang. Book | 4.06 | ||
| Price to Free Cashflow | 471.84 | ||
| Price to Sales | 9.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.78% | ||
| Return on Equity | -6.21% | ||
| Operating Margin | -27.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 5.79 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmaCorp Rx Inc. is a Canada-based pharmacy. The Company operates three pharmacies in Western and Eastern Canada. The Company provides various products and services, including custom compounding specialization services, prescription drug sales, hormone and wellness consultations, professional vitamins and supplements, weight and lifestyle management solutions, and free city-wide delivery. It sells drugs prescribed by physicians and provides optional free compliance packaging to help customers sort and remember their medication doses. In addition to in-store service, online, text and phone app order and refill options are available for prescriptions 24 hours a day, seven days a week. It carries complete lines of vitamins and supplements as an add-on to its prescription drug, custom compounding specialization and consulting businesses. Through its Simple Solution Weight Loss brand, it operates Ideal Protein clinic, which offers coaching, ketogenic food products and support to clients.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 1st, 2021
- Public Since
- May 16th, 2022
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 117,295,525
- Address
- 3603 Selinger Crescent, REGINA, S4V2H7
- Web
- Phone
- Auditors
- MNP LLP
Similar to PCRX
Astron Connect
TSX Venture Exchange
CanadaBis Capital
TSX Venture Exchange
DavidsTea
TSX Venture Exchange
High Tide
TSX Venture Exchange
Rocky Mountain Liquor
TSX Venture Exchange
FAQ
As of Today at 04:37 UTC, shares in PharmaCorp Rx are trading at CA$0.48. This share price information is delayed by 15 minutes.
Shares in PharmaCorp Rx last closed at CA$0.48 and the price had moved by +126.19% over the past 365 days. In terms of relative price strength the PharmaCorp Rx share price has outperformed the Toronto Stock Exchange 300 Composite Index by +101.1% over the past year.
There is no consensus recommendation for this security.
Find out morePharmaCorp Rx does not currently pay a dividend.
PharmaCorp Rx does not currently pay a dividend.
PharmaCorp Rx does not currently pay a dividend.
To buy shares in PharmaCorp Rx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.48, shares in PharmaCorp Rx had a market capitalisation of CA$55.72m.
Here are the trading details for PharmaCorp Rx:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: PCRX
Based on an overall assessment of its quality, value and momentum PharmaCorp Rx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PharmaCorp Rx. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -32.54%.
As of the last closing price of CA$0.48, shares in PharmaCorp Rx were trading -12.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PharmaCorp Rx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on PharmaCorp Rx's directors